The long term goal of this award is to support Dr. Puneet Opal in his efforts to become an independent clinician scientist advancing our understanding of, and ability to treat, neurodegenerative diseases. He must build on his strong neuroscience and neurology background with intensive training in neurogenetics and the creation and analysis of animal models for human diseases. Dr. Zoghbi's laboratory, pioneering as it has been in the field of neurogenetics, is an ideal environment for such training. This project focuses on the pathogenesis of spinocerebellar ataxia type I (SCAI), a dominantly inherited disease belonging to a family of disorders caused by the expansion of a glutamine repeat tract. SCAI has proven an excellent model of polyglutamine toxicity, and the Scal mouse line is arguably the most thoroughly characterized of all polyglutamine animal models. How the expanded protein damages neurons, and why only certain populations of neurons are vulnerable in a given polyglutamine disease, are important issues to be resolved, from both a basic science and a clinical standpoint. Evidence from cell culture, Scal fly and mouse models suggests that expanded ataxin-1, unlike its wild-type counterpart, tends to misfold and resist degradation. The candidate will test the ability of protein chaperones -members of the family of heat shock proteins that are known to help modulate and clear misfolded proteins-to mitigate neurodegeneration. Since it is likely that ataxin-1 interacts with cell-specific proteins that make Purkinje cells vulnerable to degeneration, the candidate will also probe the role of the leucine-rich acidic nuclear protein (LANP) in SCAI pathogenesis. This protein's high expression in Purkinje cells and strong interaction with mutant ataxin-1 suggest it might confer upon these cells selective vulnerability. Aberrant protein folding and selective neuronal damage are hallmarks of not just the polyglutamine disorders but also diseases such as Parkinson's and Alzheimer's, so the results of this project should have broad ramifications for a number of neurodegenerative conditions

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08NS002246-06
Application #
6910732
Study Section
NST-2 Subcommittee (NST)
Program Officer
Gwinn, Katrina
Project Start
2000-09-28
Project End
2006-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
6
Fiscal Year
2005
Total Cost
$126,714
Indirect Cost
Name
Northwestern University at Chicago
Department
Neurology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Kular, Rupinder K; Cvetanovic, Marija; Siferd, Steve et al. (2009) Neuronal differentiation is regulated by leucine-rich acidic nuclear protein (LANP), a member of the inhibitor of histone acetyltransferase complex. J Biol Chem 284:7783-92
Paganoni, Sabrina; Seelaus, Christina A; Ormond, Kelly E et al. (2008) Association of spinocerebellar ataxia type 3 and spinocerebellar ataxia type 8 microsatellite expansions: genetic counseling implications. Mov Disord 23:154-5
Paganoni, Sabrina; Naidech, Andrew M; Opal, Puneet (2007) Huntington's disease presenting as postsurgical psychosis. Mov Disord 22:1209-10
Opal, Puneet; Garcia, Jesus J; McCall, Alanna E et al. (2004) Generation and characterization of LANP/pp32 null mice. Mol Cell Biol 24:3140-9
Opal, Puneet; Garcia, Jesus J; Propst, Friedrich et al. (2003) Mapmodulin/leucine-rich acidic nuclear protein binds the light chain of microtubule-associated protein 1B and modulates neuritogenesis. J Biol Chem 278:34691-9